PPBTNasdaqPharmaceutical PreparationsFiscal year ends December 31

PURPLE BIOTECH LTD.

Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Mar 19, 2026

$1.08−0.06 (-5.26%)

Close on Oct 19, 2026

Market cap: –
P/E (TTM): 40.0
Dividend yield: –

PURPLE BIOTECH LTD. balance sheet

Annual Quarterly

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31	FY 2018 2018-12-31	FY 2017 2017-12-31	FY 2016 2016-12-31	FY 2015 2015-12-31	FY 2014 2014-12-31
Cash & Equivalents	8.72	7.40	14	15	11	11	4.39	5.16	3.95	6.76	11	1.31
Cash & Short-Term Investments	8.72	7.40	14	15	11	11	4.39	5.16	3.95	6.76	11	1.31
Other Current Assets	0.29	0.38	0.38	1.14	1.27	0.98	1.91	1.83	0.55	0.24	–	–
Total Current Assets	9.87	8.91	16	33	48	59	8.30	8.51	7.98	15	–	–
Property, Plant & Equipment	0.12	0.12	0.15	0.22	0.28	0.18	0.04	0.04	0.03	0.02	–	–
Operating Lease Right-of-Use Assets	0.22	0.16	0.32	0.47	0.62	0.79	0.21	–	–	–	–	–
Intangible Assets	7.36	28	28	21	20	20	6.17	6.17	6.17	–	–	–
Other Long-Term Assets	0.01	0.01	0.01	0.01	0.01	–	–	–	–	–	–	–
Total Assets	18	37	44	55	70	84	15	15	14	15	–	–
Current Portion of Leases	0.24	0.18	0.19	0.19	0.20	0.21	0.20	–	–	–	–	–
Total Current Liabilities	7.75	3.99	9.70	7.06	4.25	3.10	3.55	3.31	3.97	1.27	–	–
Long-Term Leases	–	–	0.16	0.32	0.55	0.69	0.03	–	–	–	–	–
Operating Lease Liabilities	0.24	0.18	0.38	0.59	0.88	1.05	0.22	–	–	–	–	–
Deferred Tax Liabilities	–	–	–	–	59	41	21	33	28	13	9.00	–
Total Liabilities	7.91	4.13	10	7.52	5.09	4.05	3.86	3.72	5.50	1.53	–	–
Additional Paid-In Capital	152	148	133	126	124	119	47	45	36	31	–	–
Retained Earnings	-171	-145	-137	-118	-96	-78	-50	-44	-38	-26	–	–
Shareholders' Equity	9.71	33	34	47	65	79	10	11	7.41	13	–	–
Noncontrolling Interest	-0.06	0.05	0.09	0.19	0.28	0.36	0.44	0.48	1.28	–	–	–
Total Equity	9.66	33	34	47	65	80	11	11	8.69	13	9.43	0.77
Total Liabilities & Equity	18	37	44	55	70	84	15	15	14	15	–	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Dec 31, 2025

Profitability, FY

Gross margin: –
Operating margin: –
Net margin: –
Return on equity, FY2025: -124.0%

Financial strength

Current ratio: 1.27
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 112.4%

Valuation

P/E ratio: 40.0
Price to sales: –
Price to book: –
Dividend yield: –